加载中
NASDAQHealthcareBiotechnology
最新数据
US$16.55
−US$0.44 · -2.59%
Syndax Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm focused on developing innovative therapies for cancer. Among its leading investigational products are SNDX-5613, currently undergoing Phase 1/2 clinical assessment, which targets the Menin-mixed lineage leukemia 1 protein interaction for treating MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML). Another significant candidate is SNDX-6352, or axatilimab, a monoclonal antibody designed to block the colony stimulating factor 1 (CSF-1) receptor, intended for patients suffering from chronic graft versus host disease (cGVHD). The company is additionally progressing Entinostat. Syndax has also established strategic collaborations, including a research and development agreement with the National Cancer Institute, a clinical trial agreement with the Eastern Cooperative Oncology Group, and a license agreement with Kyowa Hakko Kirin Co., Ltd. Founded in 2005, Syndax Pharmaceuticals, Inc. maintains its corporate headquarters in Waltham, Massachusetts.
前收盘价
US$16.55
−US$0.44 · -2.59%
盘前
US$13.77
−US$2.78 · -16.80%
10月13日 4:00 ET
盘中时间采用ET。市场数据可能有所延迟。
Syndax Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm focused on developing innovative therapies for cancer. Among its leading investigational products are SNDX-5613, currently undergoing Phase 1/2 clinical assessment, which targets the Menin-mixed lineage leukemia 1 protein interaction for treating MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML). Another significant candidate is SNDX-6352, or axatilimab, a monoclonal antibody designed to block the colony stimulating factor 1 (CSF-1) receptor, intended for patients suffering from chronic graft versus host disease (cGVHD). The company is additionally progressing Entinostat. Syndax has also established strategic collaborations, including a research and development agreement with the National Cancer Institute, a clinical trial agreement with the Eastern Cooperative Oncology Group, and a license agreement with Kyowa Hakko Kirin Co., Ltd. Founded in 2005, Syndax Pharmaceuticals, Inc. maintains its corporate headquarters in Waltham, Massachusetts.
日内区间
当前US$16.55
52周区间
当前US$16.55
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
持有
估值
30
偏贵
情绪
60
多空交织
风险
34
中等风险
动量
70
动能增强
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Syndax Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm focused on developing innovative therapies for cancer. Among its leading investigational products are SNDX-5613, currently undergoing Phase 1/2 clinical assessment, which targets the Menin-mixed lineage leukemia 1 protein interaction for treating MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML). Another significant candidate is SNDX-6352, or axatilimab, a monoclonal antibody designed to block the colony stimulating factor 1 (CSF-1) receptor, intended for patients suffering from chronic graft versus host disease (cGVHD). The company is additionally progressing Entinostat. Syndax has also established strategic collaborations, including a research and development agreement with the National Cancer Institute, a clinical trial agreement with the Eastern Cooperative Oncology Group, and a license agreement with Kyowa Hakko Kirin Co., Ltd. Founded in 2005, Syndax Pharmaceuticals, Inc. maintains its corporate headquarters in Waltham, Massachusetts.
日内区间
当前US$16.55
52周区间
当前US$16.55
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 1.72亿 USD | 2368万 USD | — | — | 1.4亿 USD |
| 销货成本 | 697万 USD | 82.6万 USD | — | — | — |
| 毛利 | 1.65亿 USD | 2285.4万 USD | — | — | 1.4亿 USD |
| 研究与开发 | 2.59亿 USD | 2.42亿 USD | 1.63亿 USD | 1.18亿 USD | 8824.8万 USD |
| 销售、一般及管理费用 | 1.8亿 USD | 1.21亿 USD | 6692.2万 USD | 3325.8万 USD | 2524.1万 USD |
| 营业费用 | 4.38亿 USD | 3.63亿 USD | 2.3亿 USD | 1.52亿 USD | 1.13亿 USD |
| 利息收入 | 2273万 USD | 2609万 USD | 2116.3万 USD | 587.2万 USD | 40.3万 USD |
| 利息支出 | 3378.5万 USD | 492.9万 USD | 20.8万 USD | 313.7万 USD | 189.9万 USD |
| 折旧和摊销 | 6000 USD | 8000 USD | 1.2万 USD | 3.3万 USD | 4.3万 USD |
| 营业利润 | −2.73亿 USD | −3.4亿 USD | −2.3亿 USD | −1.52亿 USD | 2622万 USD |
| 净利润 | −2.85亿 USD | −3.19亿 USD | −2.09亿 USD | −1.49亿 USD | 2492.6万 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI5468.17万0.00%2.3万亿 USD0.03%US$381.57-0.10%
State Street SPDR S&P Biotech ETFXBI4260.96万0.43%103.03亿 USD0.35%US$151.4-1.54%
iShares Russell 2000 ETFIWM3933.94万0.05%787.4亿 USD0.19%US$277.9-0.37%
Vanguard Extended Market ETFVXF1989.04万0.02%954亿 USD0.05%US$233.52-0.63%
iShares Russell 2000 Growth ETFIWO1394.85万0.10%139.17亿 USD0.24%US$353.71-0.86%
iShares Biotechnology ETFIBB1077万0.10%108.2亿 USD0.44%US$204.26-1.08%
Vanguard Russell 2000 ETFVTWO987.37万0.05%180亿 USD0.06%US$112.27-0.35%
Schwab U.S. Small-Cap ETFSCHA781.5万0.04%218.24亿 USD0.03%US$32.66-0.40%Vanguard Morningstar Total Stock Market ETFVTIState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOiShares Biotechnology ETFIBBVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHAAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
